A Study of Balapiravir in Patients With Dengue Virus Infection

Inclusion Criteria: * male patients, 18-65 years of age * dengue virus infection (confirmed by NS1 strip test) with symptom onset \</=48 hours before first study drug administration * patients and their partners of childbearing potential must use 2 forms of contraception until 3 months after receiving the last dose of study drug * BMI between 18 and 35 Exclusion Criteria: * positive test at screening for HIV using point of care test, or known HIV infection * history of any disease known to cause significant alteration in immunologic function or autoimmune disease * patients taking steroid or other immuno-suppressive therapies * positive test for drugs of abuse or alcohol using point of care test * clinically significant abnormal laboratory test results which are deemed unassociated with dengue infection or, alternatively, are diagnostic of dengue shock syndrome